MRKMerck Sharp & Dohme LLCFinished
Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522)
Triple Negative Breast Neoplasms
2Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.9
5 insiders sold shares within a month
Since Aug 13, 2026 · was worth 5, fading over time
Worry score2
Score over time
- Stage
- Phase 3
- Patients
- 1,174 (final count)
- Started
- Mar 7, 2017
- Main results expected
- Oct 14, 2025
- Fully finished
- Oct 14, 2025
- Results posted
- Oct 22, 2026
What counts as success
The trial's main goal(s), called the “primary outcome.”
Pathological Complete Response (pCR) Rate Using the Definition of ypT0/Tis ypN0 (i.e., no Invasive Residual in Breast or Nodes; Noninvasive Breast Residuals Allowed) as Assessed at the Time of Definitive Surgery in All Participants
Measured over: Up to approximately 27-30 weeks
Event-free Survival (EFS) in All Participants
Measured over: Up to approximately 102 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.9, since 2026-08-13, fades (half-life)
Raw record changes
- none yet
Trial ID NCT03036488 · record last updated 2026-10-22 · checked 2026-11-09 15:47 UTC